Form 4: Alnylam Director Phillip A. Sharp Acquires Stock Options

Director Phillip A. Sharp acquired 5,228 stock options in Alnylam Pharmaceuticals on May 16, 2024.

Summary

• On May 16, 2024, Phillip A. Sharp, a director of Alnylam Pharmaceuticals, Inc., acquired 5,228 stock options.
• The options have an exercise price of $151.22.
• These options vest fully on the earlier of the first anniversary of the grant date (May 16, 2025) or the date of retirement or resignation, provided such date is no more than 90 days prior to the anniversary.
• The options expire on May 16, 2034.
• Following the transaction, Sharp directly owns 5,228 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This is a routine disclosure related to executive compensation and insider transactions, common in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their compensation packages to align executive interests with shareholder value.
• The vesting schedules and exercise prices are generally in line with industry standards for similar roles and company sizes.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates